Advertisement
Review Article| Volume 50, ISSUE 1, P21-36, March 2023

Attention-Deficit/Hyperactivity Disorder Across the Spectrum

From Childhood to Adulthood

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Primary Care: Clinics in Office Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sharma A.
        • Couture J.
        A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD).
        Ann Pharmacother. 2014; 48: 209-225
        • Wetterer L.
        Attention-Deficit/Hyperactivity Disorder: AAP Updates Guideline for Diagnosis and Management.
        Am Fam Physician. 2020; 102: 58-60
        • Kessler R.C.
        • Adler L.
        • Barkley R.
        • et al.
        The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.
        Am J Psychiatry. 2006; 163: 716-723
        • Franke B.
        • Michelini G.
        • Asherson P.
        • et al.
        Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan.
        Eur Neuropsychopharmacol. 2018; 28: 1059-1088
      1. Attention-Deficit/Hyperactivity Disorder in Children and Teens: What You Need to Know. National Institute of Mental Health (NIMH).
        (Available at:) (Accessed May 12, 2022)
        • Faraone S.V.
        • Larsson H.
        Genetics of attention deficit hyperactivity disorder.
        Mol Psychiatry. 2019; 24: 562-575
        • Faraone S.V.
        • Banaschewski T.
        • Coghill D.
        • et al.
        The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder.
        Neurosci Biobehav Rev. 2021; 128: 789-818
      2. CDC. Research on ADHD | CDC. Centers for Disease Control and Prevention.
        (Available at:) (Accessed May 12, 2022)
        • Millichap J.G.
        Etiologic Classification of Attention-Deficit/Hyperactivity Disorder.
        Pediatrics. 2008; 121: e358-e365
        • Thapar A.
        • Cooper M.
        • Jefferies R.
        • et al.
        What causes attention deficit hyperactivity disorder?.
        Arch Dis Child. 2012; 97: 260-265
        • Botting N.
        • Powls A.
        • Cooke R.W.I.
        • et al.
        Attention Deficit Hyperactivity Disorders and Other Psychiatric Outcomes in Very Low Birthweight Children at 12 Years.
        J Child Psychol Psychiatry. 1997; 38: 931-941
        • Eme R.
        ADHD: an integration with pediatric traumatic brain injury.
        Expert Rev Neurother. 2012; 12: 475-483
        • Stahl S.M.
        Stahl’s essential psychopharmacology: neuroscientific basis and practical applications.
        5th ed. Cambridge University Press, 2021https://doi.org/10.1017/9781108975292
        • Vance A.
        • Silk T.J.
        • Casey M.
        • et al.
        Right parietal dysfunction in children with attention deficit hyperactivity disorder, combined type: a functional MRI study.
        Mol Psychiatry. 2007; 12: 826-832
        • American Psychiatric Association
        Diagnostic and statistical manual of mental disorders.
        5th edition. American Psychiatric Association, Washington, DC2013
        • Felt B.T.
        • Biermann B.
        • Christner J.G.
        • et al.
        Diagnosis and Management of ADHD in Children.
        Am Fam Physician. 2014; 90: 456-464
        • Instanes J.T.
        • Klungsøyr K.
        • Halmøy A.
        • et al.
        Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review.
        J Atten Disord. 2018; 22: 203-228
      3. NHS. Attention deficit hyperactivity disorder (ADHD) - Symptoms. nhs.uk.
        (Available at:) (Accessed May 12, 2022)
        • Larson K.
        • Russ S.A.
        • Kahn R.S.
        • et al.
        Patterns of Comorbidity, Functioning, and Service Use for US Children With ADHD, 2007.
        Pediatrics. 2011; 127: 462-470
        • Gnanavel S.
        • Sharma P.
        • Kaushal P.
        • et al.
        Attention deficit hyperactivity disorder and comorbidity: A review of literature.
        World J Clin Cases. 2019; 7: 2420-2426
      4. NICE Guidelines - Attention deficit hyperactivity disorder: diagnosis and management.
        (Available at:) (Accessed March 1, 2022)
        • Heal D.J.
        • Smith S.L.
        • Gosden J.
        • et al.
        Amphetamine, past and present – a pharmacological and clinical perspective.
        J Psychopharmacol Oxf Engl. 2013; 27: 479-496
        • Morton W.A.
        • Stockton G.G.
        Methylphenidate Abuse and Psychiatric Side Effects.
        Prim Care Companion J Clin Psychiatry. 2000; 2: 159-164
      5. Controlled Substance Schedules.
        (Available at:) (Accessed January 23, 2022)
        • Stevens J.R.
        • Wilens T.E.
        • Stern T.A.
        Using Stimulants for Attention-Deficit/Hyperactivity Disorder: Clinical Approaches and Challenges.
        Prim Care Companion CNS Disord. 2013; 15 (PCC): 12f01472
      6. Food and Drug Administration. Adderall. FDA Label.
        (Available at:) (Accessed March 1, 2022)
        • McVoy M.
        • Findling R.
        Clinical manual of child and adolescent psychopharmacology. Third.
        American Psychiatric Association Publishing, Arlington, VA2017
      7. Food and Drug Administration. Azstarys. HIGHLIGHTS OF PRESCRIBING INFORMATION.
        (Available at:) (Accessed March 1, 2022)
        • Kimko H.C.
        • Cross J.T.
        • Abernethy D.R.
        Pharmacokinetics and Clinical Effectiveness of Methylphenidate.
        Clin Pharmacokinet. 1999; 37: 457-470
      8. Food and Drug Administration. RITALIN and RITALIN-SR. HIGHLIGHTS OF PRESCRIBING INFORMATION.
        (Available at:) (Accessed March 1, 2022)
        • Adesman A.
        ADHD Medication Guide.
        (Available at:) (Accessed April 12, 2022)
        • Banaschewski T.
        • Roessner V.
        • Dittmann R.W.
        • et al.
        Non–stimulant medications in thetreatment of ADHD.
        European Child & Adolescent Psychiatry. 2004; 13: i102-i116https://doi.org/10.1007/s00787-004-1010-x
        • Hanwella R.
        • Senanayake M.
        • de Silva V.
        Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis.
        BMC Psychiatry. 2011; 11: 176https://doi.org/10.1186/1471-244X-11-176
        • Newcorn J.H.
        • Kratochvil C.J.
        • Allen A.J.
        • et al.
        Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response.
        American Journal of Psychiatry. 2008; 165: 721-730https://doi.org/10.1176/appi.ajp.2007.05091676
        • Lamb Y.N.
        Viloxazine: Pediatric First Approval.
        Pediatric Drugs. 2021; 23: 403-409https://doi.org/10.1007/s40272-021-00453-3
      9. Food and Drug Administration. Concerta. HIGHLIGHTS OF PRESCRIBING INFORMATION.
        (Available at:) (Accessed March 1, 2022)
        • Cortese S.
        • Adamo N.
        • Giovane C.D.
        • et al.
        Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
        Lancet Psychiatry. 2018; 5: 727-738
        • The MTA Cooperative Group
        A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder.
        Arch Gen Psychiatry. 1999; 56: 1073-1086
        • Barkley R.A.
        Psychosocial treatments for attention-deficit/hyperactivity disorder in children.
        J Clin Psychiatry. 2002; 63: 36-43
        • Den Heijer A.E.
        • Groen Y.
        • Tucha L.
        • et al.
        Sweat it out? The effects of physical exercise on cognition and behavior in children and adults with ADHD: a systematic literature review.
        J Neural Transm. 2017; 124: 3-26
      10. HealthyChildren.org - From the American Academy of Pediatrics. HealthyChildren.org.
        (Available at:) (Accessed May 11, 2022)
        • Scassellati C.
        • Bonvicini C.
        • Faraone S.V.
        • et al.
        Biomarkers and Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analyses.
        J Am Acad Child Adolesc Psychiatry. 2012; 51: 1003-1019.e20